ADGI - Adagio Therapeutics, Inc. Stock Price, Fair Value and News
2.39USD-0.05 (-2.05%)Delayed as of 17 May 2024, 02:05 pm ET
Market Summary
USD2.39-0.05
Delayedas of 17 May 2024, 02:05 pm-2.05%
ADGI Stock Price
View Fullscreen
ADGI RSI Chart
ADGI Valuation
ADGI Price/Earnings (Trailing)
ADGI Profitability
ADGI Fundamentals
ADGI Earnings
Breaking Down ADGI Revenue
52 Week Range
2.45
(Low)(High)
Last 7 days
8.0%
Last 30 days
-10.0%
Last 90 days
-41.9%
How does ADGI drawdown profile look like?
ADGI Financial Health
ADGI Investor Care
Tracking the Latest Insider Buys and Sells of Adagio Therapeutics, Inc.
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Sep 01, 2022 | hering david | bought | 36,160 | 4.52 | 8,000 | chief executive officer |
| Aug 19, 2022 | elia marc | bought | 2,700,160 | 4.62 | 584,451 | - |
| Aug 18, 2022 | elia marc | bought | 5,454,520 | 4.31 | 1,265,550 | - |
| Aug 17, 2022 | elia marc | bought | 4,040,000 | 4.04 | 1,000,000 | - |
| Mar 03, 2022 | adimab, llc | sold | - | - | -1,158,090 | - |
| Aug 10, 2021 | mcguire terrance | bought | 8,500,000 | 17.00 | 500,000 | - |
| Aug 10, 2021 | mcguire terrance | acquired | - | - | 8,031,700 | - |
| Aug 10, 2021 | redmile group, llc | bought | 24,990,000 | 17.00 | 1,470,000 | - |
| Aug 10, 2021 | redmile group, llc | acquired | - | - | 1,920,960 | - |
| Aug 10, 2021 | adimab, llc | acquired | - | - | 25,860,700 | - |
Which funds bought or sold ADGI recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| May 15, 2024 | Tower Research Capital LLC (TRC) | added | 195 | 50,689 | 72,465 | -% |
| May 15, 2024 | Schonfeld Strategic Advisors LLC | new | - | 186,590 | 186,590 | -% |
| May 15, 2024 | Mariner, LLC | reduced | -2.69 | 3,998 | 45,372 | -% |
| May 15, 2024 | Point72 Asia (Singapore) Pte. Ltd. | added | 4,102 | 326,407 | 333,448 | 0.09% |
| May 15, 2024 | Bain Capital Life Sciences Investors, LLC | reduced | -7.1 | 357,606 | 7,990,200 | 0.64% |
| May 15, 2024 | Laurion Capital Management LP | unchanged | - | 8,037 | 71,373 | -% |
| May 15, 2024 | 683 Capital Management, LLC | reduced | -3.47 | 1,245,000 | 15,429,000 | 1.13% |
| May 15, 2024 | TWO SIGMA INVESTMENTS, LP | added | 138 | 378,774 | 602,779 | -% |
| May 15, 2024 | MILLENNIUM MANAGEMENT LLC | added | 234 | 4,967,200 | 6,763,640 | -% |
| May 15, 2024 | Redmile Group, LLC | unchanged | - | 720,362 | 6,396,820 | 0.23% |
Are Funds Buying or Selling ADGI?
Calls
Puts
Net Call Options
No. of Funds
Unveiling Adagio Therapeutics, Inc.'s Major ShareHolders
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2024 | maverick capital ltd | 8.5% | 9,343,949 | SC 13G | |
| Feb 12, 2024 | deep track capital, lp | 7.56% | 9e+06 | SC 13G | |
| Feb 09, 2024 | fmr llc | - | 0 | SC 13G/A | |
| Jan 22, 2024 | adimab, llc | 19.7% | 21,687,906 | SC 13D/A | |
| Sep 11, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Aug 19, 2022 | m28 capital management lp | 8.50% | 9,248,250 | SC 13D/A | |
| Jul 05, 2022 | mithril ii lp | 10.2% | 11,241,580 | SC 13D/A | |
| Jun 24, 2022 | population health equity partners iii, l.p. | 33% | 359,662 | SC 13D/A | |
| Jun 24, 2022 | m28 capital management lp | 5.78% | 6,398,250 | SC 13D/A |
Recent SEC filings of Adagio Therapeutics, Inc.
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| May 16, 2024 | 144 | Notice of Insider Sale Intent | |
| May 09, 2024 | 10-Q | Quarterly Report | |
| May 09, 2024 | 8-K | Current Report | |
| May 09, 2024 | S-8 | Employee Benefits Plan | |
| May 07, 2024 | 8-K | Current Report | |
| Apr 19, 2024 | EFFECT | EFFECT | |
| Apr 18, 2024 | ARS | ARS | |
| Apr 18, 2024 | DEF 14A | DEF 14A | |
| Apr 12, 2024 | 8-K | Current Report | |
| Apr 04, 2024 | 8-K | Current Report |
Adagio Therapeutics, Inc. News
Latest updates
Adagio Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis
Balance Sheet
(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||
| Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
| Assets | -6.0% | 215 | 229 | 275 | 315 | 351 | 383 | 425 | 485 | 556 | 620 | 686 | 398 | 117 |
| Current Assets | -6.7% | 210 | 225 | 270 | 310 | 345 | 377 | 422 | 481 | 554 | 617 | 680 | 396 | 117 |
| Cash Equivalents | -5.6% | 189 | 201 | 182 | 122 | 126 | 92.00 | 278 | 475 | 532 | 542 | 478 | 393 | 115 |
| Net PPE | 0.3% | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 0.00 | 0.00 | 0.00 | - | - | - |
| Liabilities | -28.5% | 37.00 | 52.00 | 28.00 | 34.00 | 24.00 | 27.00 | 47.00 | 70.00 | 97.00 | 62.00 | 53.00 | 38.00 | 13.00 |
| Current Liabilities | -27.7% | 36.00 | 50.00 | 27.00 | 33.00 | 22.00 | 25.00 | 46.00 | 68.00 | 96.00 | 62.00 | 53.00 | 38.00 | 13.00 |
| Shareholder's Equity | 0.6% | 178 | 177 | 246 | 282 | 327 | 356 | 377 | 415 | 459 | 558 | 633 | - | - |
| Retained Earnings | -5.9% | -775 | -732 | -658 | -618 | -568 | -533 | -488 | -443 | -392 | -292 | -209 | -148 | -65.32 |
| Additional Paid-In Capital | 4.9% | 954 | 910 | 905 | 901 | 896 | 890 | 866 | 859 | 852 | 850 | 842 | 4.00 | 0.00 |
| Shares Outstanding | 8.2% | 119 | 110 | 110 | 110 | 109 | 109 | 108 | 108 | 108 | 111 | 20.00 | 6.00 | 6.00 |
| Float | - | - | - | - | 67.00 | - | - | - | 229 | - | - | - | - | - |
Cashflow (Last 12 Months)
(In Thousands)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||
| Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 |
| Cashflow From Operations | 15.2% | -50,214 | -59,240 | -35,352 | -37,391 | -41,181 | -47,404 | -56,142 | -57,392 | -59,049 | -73,212 | -54,213 | -33,570 | -23,741 | -13,428 | -1,143 |
| Share Based Compensation | 23.8% | 5,379 | 4,344 | 4,264 | 4,677 | 5,400 | 5,905 | 7,399 | 6,361 | 1,983 | 7,856 | 5,979 | 3,342 | 587 | 148 | 7.00 |
| Cashflow From Investing | -100.2% | -140 | 77,918 | 95,135 | 32,595 | 75,036 | -138,813 | -140,837 | -17.00 | 49,000 | 137,916 | -188,627 | - | - | - | - |
| Cashflow From Financing | 27631.2% | 39,101 | 141 | 92.00 | 270 | 542 | 141 | 246 | 74.00 | 45.00 | -749 | 328,600 | 334,832 | - | 79,839 | 49,720 |
| Buy Backs | - | - | - | - | 1.00 | - | - | - | 2.00 | 2.00 | - | - | - | - | -82.00 | 85.00 |
ADGI Income Statement
2024-03-31CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands | 3 Months Ended | |||||
|---|---|---|---|---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |||||
| Operating expenses: | ||||||
| Research and development | [1] | $ 31,160 | $ 27,201 | |||
| Acquired in-process research and development | [2] | 0 | 825 | |||
| Selling, general and administrative | 14,929 | 11,045 | ||||
| Total operating expenses | 46,089 | 39,071 | ||||
| Loss from operations | (46,089) | (39,071) | ||||
| Other income: | ||||||
| Other income, net | 2,593 | 3,750 | ||||
| Total other income, net | 2,593 | 3,750 | ||||
| Net loss | (43,496) | (35,321) | ||||
| Other comprehensive income (loss) | ||||||
| Unrealized gain on available-for-sale securities, net of tax | 1 | 157 | ||||
| Comprehensive loss | $ (43,495) | $ (35,164) | ||||
| Net loss per share attributable to common stockholders, basic | $ (0.38) | $ (0.32) | ||||
| Net loss per share attributable to common stockholders,diluted | $ (0.38) | $ (0.32) | ||||
| Weighted-average common shares outstanding, basic | 115,618,209 | 108,785,519 | ||||
| Weighted-average common shares outstanding, diluted | 115,618,209 | 108,785,519 | ||||
| ||||||
ADGI Balance Sheet
2024-03-31CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 189,388 | $ 200,641 |
| Inventory | 109 | 0 |
| Prepaid expenses and other current assets | 20,386 | 24,240 |
| Total current assets | 209,883 | 224,881 |
| Property and equipment, net | 1,901 | 1,896 |
| Operating lease right-of-use asset | 1,827 | 2,229 |
| Other non-current assets | 1,857 | 175 |
| Total assets | 215,468 | 229,181 |
| Current liabilities: | ||
| Accounts payable | 1,168 | 7,953 |
| Accrued expenses | 34,003 | 40,860 |
| Operating lease liability, current | 1,134 | 1,443 |
| Other current liability | 40 | 35 |
| Total current liabilities | 36,345 | 50,291 |
| Operating lease liability, non-current | 625 | 722 |
| Other non-current liability | 0 | 700 |
| Total liabilities | 36,970 | 51,713 |
| Commitments and contingencies (Note 8) | ||
| Stockholders' equity (deficit): | ||
| Preferred stock (undesignated), $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
| Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 119,221,230 shares issued and outstanding at March 31, 2024; 110,160,684 shares issued and outstanding at December 31, 2023 | 12 | 11 |
| Additional paid-in capital | 954,063 | 909,539 |
| Accumulated other comprehensive loss | (12) | (13) |
| Accumulated deficit | (775,565) | (732,069) |
| Total stockholders' equity | 178,498 | 177,468 |
| Total liabilities, preferred stock and stockholders' equity | $ 215,468 | $ 229,181 |